| 4.413 -0.067 (-1.5%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.21 | 1-year : | 7.26 |
| Resists | First : | 5.32 | Second : | 6.21 |
| Pivot price | 4.68 |
|||
| Supports | First : | 3.87 | Second : | 3.22 |
| MAs | MA(5) : | 4.44 |
MA(20) : | 4.66 |
| MA(100) : | 5.37 |
MA(250) : | 11.06 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.7 |
D(3) : | 22.4 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 47 | Low : | 3.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SNPX ] has closed above bottom band by 24.7%. Bollinger Bands are 29.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.6 - 4.63 | 4.63 - 4.66 |
| Low: | 4.35 - 4.38 | 4.38 - 4.41 |
| Close: | 4.37 - 4.42 | 4.42 - 4.46 |
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Thu, 04 Apr 2024
What's Going On With Synaptogenix (SNPX) Stock? - Synaptogenix (NASDAQ:SNPX) - Benzinga
Tue, 19 Dec 2023
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age ... - PR Newswire
Thu, 02 Nov 2023
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of ... - PR Newswire
Thu, 07 Sep 2023
Best Penny Stocks To Buy Now? 3 Under $1 To Watch - Penny Stocks
Tue, 07 Feb 2023
Synaptogenix Inc (SNPX) Up 7.69% in Premarket Trading - InvestorsObserver
Fri, 16 Dec 2022
Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 3.9 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 22 (K) |
| EPS | -29.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.9 % |
| Return on Equity (ttm) | -19.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.15 |
| PEG Ratio | 0 |
| Price to Book value | 0.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|